These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 9209216)

  • 1. Secondary prophylaxis for visceral leishmaniasis in HIV-infected individuals.
    Pérez-Molina JA; López-Vélez ; Guerrero A
    Am J Med; 1997 Jan; 102(1):132. PubMed ID: 9209216
    [No Abstract]   [Full Text] [Related]  

  • 2. Pentamidine isethionate as secondary prophylaxis against visceral leishmaniasis in HIV-positive patients.
    Pérez-Molina JA; López-Vélez R; Montilla P; Guerrero A
    AIDS; 1996 Feb; 10(2):237-8. PubMed ID: 8838721
    [No Abstract]   [Full Text] [Related]  

  • 3. Pentamidine as secondary prophylaxis for visceral leishmaniasis in the immunocompromised host: report of four cases.
    Patel TA; Lockwood DN
    Trop Med Int Health; 2009 Sep; 14(9):1064-70. PubMed ID: 19552658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of Pentamidine As Secondary Prophylaxis to Prevent Visceral Leishmaniasis Relapse in HIV Infected Patients, the First Twelve Months of a Prospective Cohort Study.
    Diro E; Ritmeijer K; Boelaert M; Alves F; Mohammed R; Abongomera C; Ravinetto R; De Crop M; Fikre H; Adera C; Colebunders R; van Loen H; Menten J; Lynen L; Hailu A; van Griensven J
    PLoS Negl Trop Dis; 2015; 9(10):e0004087. PubMed ID: 26431253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of visceral leishmaniasis with intravenous pentamidine and oral fluconazole in an HIV-positive patient with chronic renal failure--a case report and brief review of the literature.
    Rybniker J; Goede V; Mertens J; Ortmann M; Kulas W; Kochanek M; Benzing T; Arribas JR; Fätkenheuer G
    Int J Infect Dis; 2010 Jun; 14(6):e522-5. PubMed ID: 19726213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leishmaniases and HIV/AIDS co-infections: review of common features and management experiences.
    Ali A
    Ethiop Med J; 2002 Apr; 40 Suppl 1():37-49. PubMed ID: 12802830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liposomal amphotericin B as first line and secondary prophylactic treatment for visceral leishmaniasis in a patient infected with HIV.
    Borrelli P; Imperato A; Murdaca G; Scudeletti M
    Ann Ital Med Int; 2000; 15(2):169-71. PubMed ID: 10920508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pentamidine isethionate as treatment and secondary prophylaxis for disseminated cutaneous leishmaniasis during HIV infection: case report.
    Calza L; Marinacci G; Manfredi R; Colangeli V; Fortunato L; Chiodo F
    J Chemother; 2001 Dec; 13(6):653-7. PubMed ID: 11806628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylaxis of visceral leishmaniasis in human immunodeficiency virus-infected patients.
    Laguna-del-Estal P; Moya-Mir MS
    Am J Med; 1997 Feb; 102(2):222. PubMed ID: 9217577
    [No Abstract]   [Full Text] [Related]  

  • 10. [Raised tattoos in a human-immunodeficiency-virus-infected patient].
    García-Lázaro M; Villar C; Natera C; Rivero A
    Enferm Infecc Microbiol Clin; 2009 Dec; 27(10):602-4. PubMed ID: 19419796
    [No Abstract]   [Full Text] [Related]  

  • 11. Case Report: Intravenous Pentamidine Rescue Treatment for Active Chronic Visceral Leishmaniasis in an HIV-1 Infected Patient.
    Chechi F; Corsi P; Bartolozzi D; Gaiera G; Bartoloni A; Zammarchi L
    Am J Trop Med Hyg; 2021 Nov; 106(2):639-642. PubMed ID: 34781255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discontinuation of secondary anti-leishmania prophylaxis in HIV-infected patients who have responded to highly active antiretroviral therapy.
    Berenguer J; Cosín J; Miralles P; López JC; Padilla B
    AIDS; 2000 Dec; 14(18):2946-8. PubMed ID: 11153679
    [No Abstract]   [Full Text] [Related]  

  • 13. Diffuse cutaneous dissemination of visceral leishmaniasis during human immunodeficiency virus (HIV) infection, despite negligible immunodeficiency: repeated failure of liposomal amphotericin B administration, followed by successful long-term pentamidine and paromomycin administration.
    Manfredi R; Marinacci G; Calza L; Passarini B
    Int J Antimicrob Agents; 2008 Jun; 31(6):590-2. PubMed ID: 18456464
    [No Abstract]   [Full Text] [Related]  

  • 14. Miltefosine for visceral leishmaniasis relapse treatment and secondary prophylaxis in HIV-infected patients.
    Marques N; Sá R; Coelho F; Oliveira J; Saraiva Da Cunha J; Meliço-Silvestre A
    Scand J Infect Dis; 2008; 40(6-7):523-6. PubMed ID: 18584541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Visceral leishmaniasis and HIV infection: unusual presentation with pleuropulmonary involvement, and effect of secondary prophylaxis.
    Matheron S; Cabié A; Parquin F; Mayaud C; Roux P; Antoine M; Chougnet C; Coulaud JP
    AIDS; 1992 Feb; 6(2):238-40. PubMed ID: 1558727
    [No Abstract]   [Full Text] [Related]  

  • 16. Visceral leishmaniasis therapy.
    Cascio G; Titone L
    J Chemother; 1989 Jul; 1(4 Suppl):956-9. PubMed ID: 16312721
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparative study of cutaneous leishmaniasis in human immunodeficiency virus (HIV)-infected patients and non-HIV-infected patients in French Guiana.
    Couppié P; Clyti E; Sobesky M; Bissuel F; Del Giudice P; Sainte-Marie D; Dedet JP; Carme B; Pradinaud R
    Br J Dermatol; 2004 Dec; 151(6):1165-71. PubMed ID: 15606511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concordant HIV infection and visceral leishmaniasis in Ethiopia: the influence of antiretroviral treatment and other factors on outcome.
    ter Horst R; Collin SM; Ritmeijer K; Bogale A; Davidson RN
    Clin Infect Dis; 2008 Jun; 46(11):1702-9. PubMed ID: 18419422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of liposomal amphotericin B for secondary prophylaxis of visceral leishmaniasis in HIV-infected patients.
    Molina I; Falcó V; Crespo M; Riera C; Ribera E; Curran A; Carrio J; Diaz M; Villar del Saz S; Fisa R; López-Chejade P; Ocaña I; Pahissa A
    J Antimicrob Chemother; 2007 Oct; 60(4):837-42. PubMed ID: 17684055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An HIV-positive man with tattoo induration.
    López-Medrano F; Costa JR; Rodriguez-Peralto JL; Aguado JM
    Clin Infect Dis; 2007 Jul; 45(2):220-1, 267-8. PubMed ID: 17578782
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.